메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 25, Issue 16, 2007, Pages 2156-2158
The hope for today - The promise for tomorrow: Will oncologists meet the challenge?
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;
EID: 34250199381     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.9838     Document Type: Editorial
Times cited : (5)
References (8)
  • 1
    • 34250210799 scopus 로고    scopus 로고
    • Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
    • Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 2198-2204
    • Kuebler, J.P.1    Wieand, H.S.2    O'Connell, M.J.3
  • 2
    • 2542615200 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    • Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
    • (2004) N Engl J Med , vol.350 , pp. 2343-2351
    • Andre, T.1    Boni, C.2    Mounedji-Boudiaf, L.3
  • 3
    • 34250214962 scopus 로고    scopus 로고
    • Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
    • Land SR, Kopec JA, Cecchini RS, et al: Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205-2211, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 2205-2211
    • Land, S.R.1    Kopec, J.A.2    Cecchini, R.S.3
  • 4
    • 33644834827 scopus 로고    scopus 로고
    • Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
    • Sargent DJ, Weind HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 8664-8670
    • Sargent, D.J.1    Weind, H.S.2    Haller, D.G.3
  • 5
    • 0141656847 scopus 로고    scopus 로고
    • Prognostic factors in colorectal cancer: College of American Pathologists consensus statement 1999
    • Compton C, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 124:979-994, 2000
    • (2000) Arch Pathol Lab Med , vol.124 , pp. 979-994
    • Compton, C.1    Fielding, L.P.2    Burgart, L.J.3
  • 6
    • 33644972820 scopus 로고    scopus 로고
    • Key issues in reporting common cancer specimens: Problems in pathologic staging of colon cancer
    • Compton CC: Key issues in reporting common cancer specimens: Problems in pathologic staging of colon cancer. Arch Pathol Lab Med 130:318-324, 2006
    • (2006) Arch Pathol Lab Med , vol.130 , pp. 318-324
    • Compton, C.C.1
  • 7
    • 0003809054 scopus 로고    scopus 로고
    • American Joint Committee on Cancer, ed 6, New York, NY, Springer-Verlag
    • American Joint Committee on Cancer. AJCC Cancer Staging Handbook (ed 6). New York, NY, Springer-Verlag, 2002
    • (2002) AJCC Cancer Staging Handbook
  • 8
    • 2542563257 scopus 로고    scopus 로고
    • Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?
    • Gill S, Lopinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797-1806, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 1797-1806
    • Gill, S.1    Lopinzi, C.L.2    Sargent, D.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.